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• Oxidative stress and damage were common in the β-thalassemia syndromes 
in Sri Lanka 
• Oxidative stress and damage varied both between and within thalassemia 
syndromes 
• Oxidative stress and damage tended to be worse in patients with HbE β-
thalassemia 
• Oxidative stress and damage were associated with splenectomy and 
chelation therapy 











In the β-thalassemias, oxidative stress, resulting from chronic hemolysis, globin chain 
imbalance, iron overload and depleted antioxidant defences, likely contributes to 
cell death, organ damage, anemia, hypoxia and inflammation. We assessed 
variations in these parameters in β-thalassemia syndromes in Sri Lanka.   
Between November 2017 and June 2018, we assessed children and adults attending 
two thalassemia centres in Sri Lanka: 59 patients with HbE β-thalassemia, 50 β-
thalassemia major, 40 β-thalassemia intermedia and 13 HbS β-thalassemia. Median 
age was 26.0 years (IQR 15.3-38.8), 101 (62.3%) were female and 152 (93.8%) of 
Sinhalese ethnicity. Methemoglobin, plasma hemoglobin, heme and ferritin were 
measured as sources of oxidants; plasma total antioxidant capacity, haptoglobin, 
hemopexin and vitamins C and E assessed antioxidant status; plasma thiobarbituric 
acid reactive substances and 8-hydroxy–2’–deoxyguanosine assessed oxidative 
damage; hemoglobin, plasma erythropoietin and transferrin receptor assessed 
anemia and hypoxia and plasma interleukin-6 and C-reactive protein assessed 
inflammation. Fruit and vegetable intake was determined by dietary recall. Physical 
fitness was investigated using the six-minute walk test and measurement of 
handgrip strength. 
Oxidant sources were frequently increased and antioxidants depleted, with 
consequent oxidative damage, anemia, hypoxia and inflammation. Biomarkers were 
generally most abnormal in HbE β-thalassemia and least abnormal in β-thalassemia 
intermedia but also varied markedly between individuals with the same thalassemia 
syndrome. Oxidative stress and damage were also more severe in splenectomized 
patients and/or those receiving iron chelation therapy. Less than 15% of patients ate 
fresh fruits or raw vegetables frequently, and plasma vitamins C and E were deficient 
in 132/160 (82.5%) and 140/160 (87.5%) patients respectively. Overall, physical 
fitness was poor in all syndromes and was likely due to anemic hypoxia. 
Studies of antioxidant supplements to improve outcomes in patients with 
thalassemia should consider individual patient variation in oxidative status both 










Despite being the most common monogenic diseases, the true disease burden of the 
inherited hemoglobin disorders is unknown. It is estimated that >7% of the world's 
population carry a hemoglobin variant resulting in 300,000-500,000 annual births 
with a serious hemoglobin disorder accounting for at least 3.4% of under-five deaths 
[1]. 
 
A recent survey of 23 thalassemia treatment centres in Sri Lanka identified 1219 
patients with β-thalassemia major, 360 with HbE β-thalassemia and 50 with HbS β-
thalassemia [2]. Patients with β-thalassemia major require life-long intensive clinical 
management including at least monthly blood transfusion. The clinical course of HbE 
β-thalassemia is more variable, ranging from mild to severe anemia. In both 
conditions, transfusional iron overload in the absence of early and effective iron-
chelation therapy results in liver, cardiac and endocrine dysfunction including 
impaired growth and glucose intolerance. Sickle cell disorders are less common in Sri 
Lanka and the majority of patients have the Asian haplotype associated with a 
relatively mild phenotype [3-5]. 
In the β-thalassemias, β globin chains are either absent or produced at a reduced 
rate, resulting in globin chain imbalance. Within red cells, free α-globin chains and 
unstable hemoglobins such as HbE and HbS auto-oxidise, producing methemoglobin 
(MetHb), hemichromes and free radicals. Hemichromes bind to the red cell 
membrane sequestering the band 3 protein and resulting in cell lysis [6]. Following 
hemolysis, free hemoglobin (Hb) in the plasma undergoes further oxidative 
reactions, generating free radicals and releasing free heme and iron, which are toxic. 
In the absence of an adequate supply of antioxidants, oxidant damage occurs to cell 
membranes, vascular endothelium and various organs, and a pro-inflammatory state 
can ensue [7]. In addition to host antioxidant enzyme systems, the dietary 
antioxidants vitamins C (ascorbate) and E (alpha-tocopherol) scavenge free radicals 
[8].  Vitamin C reduces MetHb, ferryl hemoglobin and globin radicals, preserves 
alpha-tocopherol in lipoproteins, and generates and preserves nitric oxide needed 
for vascular regulation. Vitamin E, a scavenger of peroxyl radicals, protects cell 
membranes from lipid peroxidation and lysis. As well as increased utilisation in 
thalassemia, dietary deficiency may also contribute to low concentrations of these 
vitamins [9,10]. 
We undertook a comprehensive assessment of oxidant, antioxidant and 
inflammatory status, and their underlying contributory factors, in patients attending 
thalassemia services in Sri Lanka. 
Materials and Methods 
Between November 2017 and May 2018, we undertook a cross-sectional study of 
children with thalassemia attending Colombo North Teaching Hospital, Ragama and 
adolescents and adults attending Hemals Thalassemia Care Unit, Mahara, Sri Lanka. 








parents/guardians was obtained. Patients who were unwell on the day of 
recruitment were excluded. 
Sampling/ recruitment procedure  
The study clinician examined the patients and reviewed case records. The primary 
diagnosis, spleen status, chelation regime, transfusion history and known genetic 
modifiers of disease severity such as α-thalassemia were recorded. Height and 
weight were measured and body mass index (BMI) in adults and BMI percentile in 
children and adolescents (<20 years) determined according to standard reference 
data [11]. 
Fruit and vegetable intake was assessed using a dietary recall questionnaire. Physical 
function was assessed by the six-minute walk test [12] and handgrip strength [13]. 
Briefly, participants walked at their own pace for 6 minutes along a 100m level 
corridor whilst observed and encouraged by a study staff member and the total 
distance walked was recorded. Using their dominant hand, each patient was asked 
to squeeze a bulb dynamometer (BaselineR, New York, USA) as tightly as they could. 
The average total amount of static force applied of three readings was recorded 
(pounds per square inch; psi).  
Finally, five millilitres of venous blood was collected and MetHb (%) and 
carboxyhemoglobin (%; CoHb) and p50 (mmHg) measured immediately (ABL-FLEX 80 
blood gas analyser with integral co-oximeter; Radiometer, Medical ApS, Akandavec, 
Denmark). Equal volumes of the remaining blood sample were transferred into EDTA 
and lithium heparin and transported immediately to the laboratory for analysis. 
Lithium heparin venous blood (2 ml) was also collected from 26 healthy adult 
volunteers for the measurement of plasma vitamin C and E. 
Laboratory analyses 
Routine hematological indices were measured in EDTA whole blood (Ac.T differential 
analyser; Beckman Coulter, Luton, UK). Anemia was defined as Hb concentration 
<11.5 g/dl in children <12 years, Hb <12.0 g/dl in females ≥12 years and males aged 
12-14 years and Hb <13.0 g/dl in males ≥15 years, and severe anemia was defined as 
Hb concentration <8.0 g/dl in adults and children > 5years or <7.0 g/dl in pregnant 
women and children < 5years [14]. Hemoglobin variants were quantified by capillary 
electrophoresis (Capillarys 2 Flex Piercing Instrument; Sebia, Lisses, France).  EDTA 
samples were then centrifuged and the plasma and buffy coats removed.  
DNA was extracted from buffy coat samples (QIAamp DNA mini –kit; # 51304, 
QIAGEN, Manchester, UK) and genotyped for the presence of triplicated α –globin 
genes and deletional forms of α-thalassemia (-α3.7/αα and α4.2/αα) using previously 
described methods [15,16]. 
Lithium heparin blood samples were centrifuged and 250ul aliquots of plasma 
transferred into light protective cryo-storage tubes. One aliquot from each patient 









collection for the vitamin C assay. All plasma samples were stored at -20°c until 
further analyses.  
Plasma hemoglobin, heme and ferritin were measured as sources of oxidants. 
Antioxidant status was evaluated by measurement of plasma total antioxidant 
capacity, haptoglobin, hemopexin and vitamins C and E. Oxidant damage was 
assessed by measurement of plasma thiobarbituric acid reactive substances (TBARS) 
and 8-hydroxy–2’–deoxyguanosine (8-oxo-dG). Plasma erythropoietin, transferrin 
receptor and nitrite assessed response to anemia and hypoxia, and inflammation 
was assessed by measurement of plasma Interleukin- 6 (IL-6) and C-reactive protein 
(CRP). Details of all assays and kits used are summarised in supplementary table S1. 
All assays were performed in accordance with the manufacturers’ guidelines and all 
samples were tested in duplicate for each biomarker. Quality controls were included 
with each batch of tests.  
Stabilised plasma samples and heparin plasma were shipped back to Oxford, UK on 
dry-ice    
Stabilised plasma samples were transferred to the Scottish Trace Element and 
Micronutrient Diagnostic and Research laboratory, Glasgow, UK for measurement of 
vitamin C, by high performance liquid chromatography (HPLC), [17] using a Waters 
auto-sampler, pump and electrochemical detection system; (Waters, Massachusetts, 
USA). 
Heparin plasma samples were transferred to the Department of Clinical 
Biochemistry, Royal Gwent Hospital, Newport, UK, for the measurement of vitamin 
E, by HPLC using an Agilent 1200 analyser and multi-wavelength detection system; 
(Agilent, California, USA).  
Statistical methods 
Demographic, clinical and laboratory categorical variables were summarized using 
counts and percentages. Continuous variables tended to have skewed distributions; 
they were described using median and interquartile range and compared using the 
Mann-Whitney U and Kruskall Wallis tests. Data analysis was performed using 
Statistical Package for Social Sciences Software (SPSS), version 26 (New York, USA). 
Ethical approval 
The study was approved by the Ethics Committee, University of Kelaniya, Sri Lanka 
(P/225/09/2017) and Oxford University Tropical Research Ethics Committee, Oxford, 
UK (OXTREC 515-13). The study was conducted in accordance with the declaration of 









The study group comprised 162 patients: 59 with HbE β-thalassemia, 50 β- 
thalassemia major, 40 β-thalassemia intermedia, and 13 HbS β-thalassemia. 1 
patient with δβ-thalassemia and 1 with sickle cell disease were excluded.  
 
In 128 (79.0%) patients in whom α-thalassemia genotype was determined, 
triplicated α-globin genes were present in 3/45 (6.7%) patients with β-thalassemia 
major, 3/42 (7.1%) HbE β-thalassemia, 19/28 (67.9%) with β-thalassemia intermedia 
and 0/13 (0.0%) with HbS β-thalassemia. Heterozygous deletional α-thalassemia was 
present in 3/45 (6.7%) patients with β-thalassemia major, 4/42 (9.5%) HbE β-
thalassemia, 3/28 (10.7%) β-thalassemia intermedia and 1/13 (7.7%) HbS β-
thalassemia. Homozygous deletional α-thalassemia was present in 1 (2.2%) patient 
with HbE β-thalassemia and 1 (3.6%) with β-thalassemia intermedia. 
 
Demography, anthropometry and clinical assessment according to diagnostic group 
are shown in table 1. In all patients, median age was 26.0 years (IQR 15.3-38.8) years 
and was lower in HbS β-thalassemia and higher in β-thalassemia intermedia than in 
the other groups. There were more females (101; 62.3%) than males overall but 
males predominated in HbS β-thalassemia. One hundred and fifty-two (93.8%) 
patients were of Sinhalese ethnicity. Low body weight occurred in 49 adults (BMI< 
18.5 kg/m2) and 15 children/adolescents (BMI percentile <5%) and was more 
common in patients with HbS β-thalassemia or HbE β-thalassemia. Only 13 adults 
(BMI >23.0 kg/m2) and 2 children/adolescents (BMI percentile >85.0%) were 
overweight. 
 
As expected, patients with β-thalassemia major had received more frequent blood 
transfusions in the previous 12 months than those in the other groups, with many 
receiving more than one blood transfusion per month. Chelation data was available 
for 160 patients, of whom 111 (69.4%) were receiving iron chelation therapy. 
Overall, 45/162 (27.8%) patients had undergone splenectomy; splenectomy was 
more common in HbE β-thalassemia and β-thalassemia major, where approximately 
1 in 3 participants were splenectomized.  
 
Oxidant and antioxidant status, oxidative damage, anemia, hypoxia and 
inflammation are summarised according to the proportion of patients with abnormal 
values in each diagnostic group (figure 1) and data summarised in figures 2-6 and 
supplementary table S2. Overall, values for these biomarkers varied both between 
diagnostic groups and between individuals with the same thalassaemia syndrome. 
Sources of oxidants (Fig 1, Fig 2a-d; Suppl Table S2) 
Nearly all patients had markedly increased concentrations of markers of hemolysis 
and iron overload. The exception was ferritin that was raised in just over 50% HbS β-
thalassemia patients (Fig 1). Median values varied significantly according to 
diagnostic group. Patients with HbE β-thalassemia had the highest concentration of 
plasma hemoglobin and heme and percentage of MetHb in whole blood. However, 









half of patients had concentrations more than 10 fold (>2830 ng/ml) above the 
upper limit of the normal range. 
Antioxidants (Fig 1, Fig 3a-e; Suppl Table S2) 
Total antioxidant capacity varied significantly according to diagnosis with marked 
deficiency in all groups except for HbS β–thalassemia where capacity was low in 46% 
patients. Concentrations of individual antioxidants also varied significantly according 
to diagnostic group. Median plasma haptoglobin was very low in all groups except 
for β-thalassemia major where 42% patients had a normal value. Hemopexin 
concentrations were low in nearly all patients with marked deficiency in HbE β-
thalassemia and β-thalassemia major. 
Vitamins C and E were markedly deficient in all diagnostic groups except for β -
thalassemia intermedia, where around half had normal vitamin C and one-third had 
normal vitamin E levels. Plasma vitamin C and E were below the lower level of 
quantitation in 86/160 (53.8%) and 130/160 (81.3%) patients respectively. In healthy 
adult volunteers, plasma vitamin C was low (<14 μmol/L) in 23/26 (88.5%) and 
vitamin E was low (<12 μmol/L) in 6/25 (24.0%) with low concentrations of both 
vitamins in 5/25 (20%; data not shown). 
Oxidant damage (Fig 1, Fig 4a -b; Suppl Table S2) 
Oxidant damage also varied markedly according to diagnosis. Plasma TBARS was 
raised in approximately three-quarters of patients with HbE β-thalassemia, two-
thirds of patients with β-thalassemia, one in five β thalassemia intermedia but was 
normal in HbS β-thalassemia. In contrast, median plasma 8-oxo-dG was raised in all 
diagnostic groups and especially in HbS β-thalassemia. 
Anemia, hypoxia and erythropoiesis (Fig 1, Fig 5a -f; Suppl Table S2) 
Biomarkers of anemia, hypoxia and erythropoiesis also varied significantly according 
to diagnostic group. Apart from 3 patients with β-thalassemia major who had been 
recently transfused, all patients were anemic. Hemoglobin concentration was lowest 
in HbE β-thalassemia. 
CarboxyHb (%) was raised in about three quarters of patients with HbE β-
thalassemia and HbS β- thalassemia and about half of patients with β-thalassemia 
intermedia. Plasma nitrite concentration was normal in most patients, but deficiency 
occurred in about one in three patients with HbE β-thalassemia and one in five with 
β-thalassemia major.  
Plasma erythropoietin and soluble transferrin receptor were markedly raised in 
nearly all patients and greatest in those with HbE β-thalassemia, where 
concentrations of each biomarker were up to 5 times greater than the upper limit of 
normal in many individuals. A right shift in the oxygen dissociation curve was 









Inflammation (Fig 1, Fig 6a -b; Suppl Table S2) 
Plasma concentrations of IL-6 varied significantly according to diagnosis and were 
within the normal range in about two-thirds to half of patients, except for those with 
HbS β-thalassemia, where levels were markedly elevated. In contrast, CRP was raised 
in only about 1 in 4 patients and was similar according to diagnosis (P=0.24). 
Dietary antioxidants 
Amongst 158/162 (97.5%) participants who completed dietary questionnaires, only 
40 (25.3%) participants reported that they ate one or more portions of fruit and/or 
raw vegetables each day. Nearly all participants (149/158; 94.3%) reported that they 
ate at least one portion of cooked vegetables each day. Dietary intake was similar in 
each diagnostic group (data not shown). 
Physical fitness (Table 2) 
Physical fitness was assessed in 54 males and 93 females. Only 2/147 (1.3%) patients 
were able to achieve ≥80% of their expected walking distance and only 2/147 (1.3%) 
patients achieved normal handgrip strength (20 psi). Walking distance and handgrip 
strength were greater in males than females (χ2 =7.59, p=0.006 and χ2 =4.23, p=0.04 
respectively) but were similar according to diagnosis.  
Effects of splenectomy (Table S3) 
Blood MetHb and plasma ferritin were significantly greater and plasma antioxidants 
hemopexin, vitamin C and vitamin E were significantly lower in splenectomized 
patients than those with intact spleens.  Plasma TBARS and CRP were also 
significantly greater in splenectomized patients. 
Effects of iron chelation (Table S3) 
Plasma ferritin and haptoglobin were significantly greater and plasma antioxidants 
hemopexin, vitamin C and vitamin E were significantly lower in patients receiving 
iron chelation therapy compared to patients who were not. Plasma TBARS was also 
significantly greater in patients who were chelated. The fraction of Carboxyhb in 
whole blood and plasma soluble transferrin receptor were both significantly lower in 
chelated patients. 
Effects of α–thalassemia and triplicated α–globin genes 
There were too few patients with concomitant α-thalassemia in each diagnostic 
group to assess the effects of α-globin genotype on oxidative stress and damage. 
Triplicated α-globin genes were detected in 25/128 (19.5%) DNA samples but most 
(19/25; 76%) were from patients with β-thalassemia intermedia, which meant it was 











As far as we are aware, this is the most comprehensive study of oxidative status in 
the β-thalassemia syndromes in South Asia. Overall, the combination of markedly 
increased sources of oxidants with antioxidant deficiency contributed to the DNA 
damage, assessed by 8-oxo-dG, in all patient groups and lipid peroxidation, assessed 
by TBARS, in HbE β-thalassemia and β-thalassemia major. Dietary deficiency of 
vitamins C and E likely contributed to poor antioxidant status. In addition, values for 
many biomarkers varied significantly both between diagnostic groups and between 
individuals with the same thalassemia syndrome. 
 
The main instigator of oxidative stress in β-thalassemia is likely to be iron, which 
participates in the Fenton reaction with hydrogen peroxide to produce reactive 
oxygen species (ROS). Iron homeostasis is controlled by hepcidin, a regulatory 
hormone produced primarily by the liver. Hepcidin synthesis is down-regulated by 
erythropoiesis and up-regulated by inflammation and increased iron. In the β-
thalassemias, hepcidin synthesis is suppressed due to increased erythropoiesis, 
which results in increased gastrointestinal iron absorption [19,20]. Iron from blood 
transfusion further contributes to increased iron stores in β-thalassemia. 
Oxidative status according to clinical group 
Raised plasma ferritin concentration, indicating increased iron stores, was present in 
the majority of patients and greatest in those with β-thalassemia major who are 
regularly transfused. In addition to excess iron, free radicals are also generated as a 
consequence of the complex interplay between unstable hemoglobins, globin chain 
imbalance and chronic haemolysis that occurs in the β-thalassemias [21].  
We found that MetHb, plasma hemoglobin and heme were greatest and plasma 
haptoglobin and hemopexin (chaperones for free Hb and heme) were lowest in HbE 
β-thalassemia, reflecting the greater degree of haemolysis in these patients. We 
have previously reported raised MetHb in HbE-β thalassemia in Sri Lanka [22]. These 
findings are consistent with the greater degree of lipid peroxidation (assessed by 
TBARS) found in the HbE β-thalassemia group. The structurally and oxidatively 
unstable HbE molecule likely underlies the greater oxidant stress and damage [23-
25]. Hemoglobin E binds to the red cell membrane band 3 with greater affinity than 
HbA or HbS, promoting cell lysis [26], and Ferryl (Fe4+) forms of HbE remain longer in 
solution and promote hemolysis and further free radical generation [27]. Anemia 
was also more severe in patients with HbE-β thalassemia than in the other diagnostic 
groups. The increased fractions of both CoHb and MetHb (unable to bind oxygen) 
would have contributed to tissue hypoxia. This is reflected in the greatest 
concentrations of erythropoietin and transferrin receptor in HbE β-thalassemia as 
responses to anemia and hypoxia. 
The structural and oxidative instability of HbS [28-30] also likely contributed to 
oxidant stress in HbS β-thalassemia and the greatest degree of DNA damage as 
assessed by plasma 8-oxo-dG. The absence of lipid peroxidation in these patients 
may be related to their greater total antioxidant capacity, younger age and much 
lower iron stores due to fewer transfusions [31,32]. Our findings relating to oxidant 









naturally occurring product of lipid peroxidation) and increased 8-oxo-dG in sickle 
cell disease compared with β-thalassemia major [33]. A right shift in the oxygen 
dissociation curve compensated for hypoxia, and was most marked in patients with 
HbS β-thalassemia (Suppl Table S2).  
Abnormalities were least in patients with β-thalassemia intermedia. These patients 
were less regularly transfused and iron stores were lower. The greater plasma 
concentrations of vitamins C and E may explain, in part, the low or normal 
concentration s of plasma TBARS in the majority of these patients. Interestingly, 
19/28 (68%) patients with normal plasma vitamin C and 13/15 (87%) with normal 
plasma vitamin E concentration were from the β -thalassemia intermedia group. 
Effects of splenectomy and chelation therapy 
Splenectomized patients had significantly greater sources of oxidant free radicals 
and decreased antioxidants, resulting in greater oxidant damage. We have 
previously reported that % MetHb was increased in splenectomized thalassemia 
patients compared to those with intact spleens [22]. Increased ferritin concentration 
has been reported in splenectomized patients with HbE β-thalassemia, β-
thalassemia intermedia and Hb H syndromes [34,35]. It is likely that abnormal red 
cells that would ordinarily be sequestered by the spleen remain in the circulation, 
increasing the potential for free radical generation. 
Decreased concentrations of antioxidants and increased oxidant damage were 
evident in patients who were chelated. This likely reflects the increased iron stores in 
this group, despite chelation therapy.  
Inflammation 
 
Both free heme and MetHb can activate endothelia to increase pro-inflammatory 
cytokines, E-selectin, adhesion molecules and platelets [36]. Increased IL-6 was 
present in about half of the patients in this study, and concentrations were greatest 
in patients with HbS β-thalassemia. IL-6 stimulates the acute phase response by 
inducing the production of CRP, which was increased in about a quarter of patients 
in each group. Our findings of greater concentrations of inflammatory cytokines in 
patients with HbS are in keeping with the findings in patients with sickle cell disease 
[33]. We have reported previously that the pro-inflammatory cytokine interleukin-8 
was elevated in many patients with HbE-β thalassemia [22]. 
Physical fitness 
It was surprising that the patients in this study had such poor physical fitness, with 
only 2 patients able to achieve a distance ≥ 80% of the expected walking distance 
and a normal handgrip strength. This likely relates to anemia, hypoxia, inflammation, 
and may also reflect underlying organ damage and vasculopathy, such as pulmonary 
hypertension. 








Antioxidant deficiency was common across all groups and especially in HbE β-
thalassemia and β-thalassemia major. We have reported previously low plasma 
vitamin C concentrations in patients with HbE β-thalassemia in Sri Lanka [22] and 
concentrations were remarkably low in this study. Low vitamin C has also been 
reported in β-thalassemia major and sickle cell disorders [9,10,37] and is likely due 
to the increased demand in protecting against oxidant stress. Additionally, the 
haptoglobin 2-2 genotype is very common in Sri Lanka and may also have 
contributed to the very low plasma vitamin C concentrations [22,38,39]. 
Despite their abundance in Sri Lanka [40], a low intake of fresh fruit and raw 
vegetables was reported by the majority of patients suggesting that dietary 
insufficiency may also have contributed to vitamin C deficiency. Low intake of fresh 
fruit and vegetables has been reported previously in Sri Lanka; <1% of adults and 
<14% of children met National daily intake recommendations [41-44]. Severe vitamin 
C deficiency results in scurvy, and we have previously reported that following 
treatment with a cautious dose of ascorbate, MetHb concentration normalised and 
clinical symptoms of scurvy improved in a patient with HbE β-thalassemia [22]. 
Similarly, in 3 patients with β-thalassemia major in India, treatment with ascorbate 
reversed purpura and joint effusions [45]. However, a concern regarding 
supplementation of all patients is that this may exacerbate iron overload through 
increased intestinal absorption of iron [46].  
Remarkably low plasma vitamin E was also found in the majority of patients. Again, 
this is likely due to the increased demands of oxidant stress. Also, as vitamin C is 
involved in vitamin E recycling [47], it follows that if vitamin C concentration is low, 
less vitamin E will be recycled and concentrations will fall.  
Although plasma concentrations of vitamins C and E are reduced during the acute 
phase response [48], the normal CRP levels in most of our patients indicate true 
deficiency of these micronutrients. Low concentrations of both vitamins have been 
reported previously in β-thalassemia, sickle-cell anemia, HbE β-thalassemia and α-
thalassemia [9,10,49-51]; and low plasma vitamin E has been described in Sri Lankan 
females diagnosed with phrynoderma [52].  
 
Antioxidant intervention studies 
Antioxidant interventions in patients with hemoglobinopathies have been evaluated 
in several studies with mixed results. Fermented papaya ameliorated oxidant stress 
in HbE β-thalassemia, β-thalassemia major and β-thalassemia intermedia [53]. 
Vitamin E supplements are considered safe, unless given in excess [54], and oral 
vitamin E improved oxidant stress in β-thalassemia intermedia [55,56] and total 
antioxidant capacity in HbE-trait [57]. Vitamin C and E supplements worsened 
hemolysis in sickle cell anemia [58] and did not reduce oxidant damage in β-
thalassemia major although plasma concentrations of both vitamins increased and 
bilirubin concentration decreased [59]. In a recent study of Thai patients with HbE β-
thalassemia, antioxidant cocktails increased hemoglobin concentration and 









oxidative status and damage both between and within the thalassemia syndromes 
indicate that participants should be selected on an individual basis for inclusion in 
future intervention studies.  
Strengths and limitations 
A strength of our study is that we evaluated a broad range of variables related to 
oxidative status in four important hemoglobinopathy syndromes and, to our 
knowledge, this is the first study to describe oxidative status in patients with HbS β-
thalassemia. Employing single methods and same kit lot numbers and quality 
controls for each biomarker assay and minimizing variation in sample collection, 
storage, preparation and analysis allowed for us to compare results between the 
diagnostic groups. However, our study had several limitations. Limited sample 
volume and laboratory resources restricted the choice of laboratory assays, including  
state-of-the-art methodologies for determining parameters of lipid peroxidation. 
Also, measurement of other antioxidants such as albumin, free thiols and uric acid 
would have added to our assessment of oxidative status and helped in interpreting 
total plasma antioxidants. We were also unable to assess the effects of 
coinheritance of α–thalassemia or triplicated α-globin genes because the number of 
patients with abnormal α–globin genotypes in each diagnostic group was too few.  
 
Conclusion 
Markedly increased oxidant stress results in significant oxidant damage in the 
thalassemia syndromes in Sri Lanka. Antioxidant deficiency was evident in all 
syndromes and is likely compounded by dietary vitamin C and E deficiency. There is 
an urgent need for clinical trials of antioxidants, such as vitamins C and E, in 
thalassemia, as they offer the potential for significant and affordable clinical 
benefits. However, sources of oxidants, antioxidant status and oxidant damage 
varied both between and within the thalassemia syndromes, emphasising the need 
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Table 1. Demography, anthropometry, transfusion history, chelation and spleen 










































































































4/31 (12.9) 0/43 (0.0) 1/4 (25.0) 8/33 (24.2) 
Children and 
adolescents <20 years 
of age 

















No (%) underweight 
(<5th centile) 




1/18 (5.6) 0/16 (0.0) 1/9 (11.1) 0/7 (0.0) 
Transfusion history* 






















































• $ WHO BMI cut-offs for Asia Pacific countries. 
• *It was not possible to obtain a complete transfusion history for some 
patients because medical records were either incomplete or unavailable.  






























Total Distance walked in 6 minutes (metres) 


















(350.9 – 426.99) 
 
[278.0-476.6] 


































































Handgrip strength [psi] 





























(4.0 – 7.25) 
[1.0-10.5] 
Notes 
1. Distance achieved expressed as % of the expected distance for an age and sex 












Figure 1. Heat map to show percentage of patients with abnormal values in each 
diagnostic group. 
 
Figure 2. Sources of oxidants according to diagnostic group. Horizontal lines show 
the median value, box length is the interquartile range and whiskers show the range 
except for outlying values ≥1.5 box lengths from the upper and lower edge of the 
box which are shown as open circles. 
Reference lines - -- - -- - -- represent the upper limit of normal range  
Reference lines − − − − − − represent the lower limit of normal range 
 
Figure 3. Antioxidants according to diagnostic group. Horizontal lines show the 
median value, box length is the interquartile range and whiskers show the range 
except for outlying values 1.5 to 3, or >3, box lengths from the upper and lower edge 
of the box which are shown as open circles and stars respectively. 
Reference lines - -- - -- - -- represent the upper limit of normal range 
Reference lines − − − − − − represent the lower limit of normal range 
 
Figure 4. Oxidant damage according to diagnostic group. 
Horizontal lines show the median value, box length is the interquartile range and 
whiskers show the range except for outlying values 1.5 to 3, or >3, box lengths from 
the upper and lower edge of the box which are shown as open circles and stars 
respectively. 
Reference lines - -- - -- - -- represent the upper limit of normal range  
Reference lines − − − − − − represent the lower limit of normal range 
 
Figure 5. Anemia, hypoxia and erythropoiesis according to diagnostic group. 
Horizontal lines show the median value, box length is the interquartile range and 
whiskers show the range except for outlying values 1.5 to 3, or >3, box lengths from 
the upper and lower edge of the box which are shown as open circles and stars 
respectively. 
Reference lines - -- - -- - -- represent the upper limit of normal range   
Reference lines − − − − − − represent the lower limit of normal range 
 
Figure 6. Inflammation according to diagnostic group. 
Horizontal lines show the median value, box length is the interquartile range and 
whiskers show the range except for outlying values 1.5 to 3, or >3, box lengths from 
the upper and lower edge of the box which are shown as open circles and stars 
respectively. 
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• Oxidative stress and damage were common in the β-thalassemia syndromes 
in Sri Lanka 
• Oxidative stress and damage varied both between and within thalassemia 
syndromes 
• Oxidative stress and damage tended to be worse in patients with HbE β-
thalassemia 
• Oxidative stress and damage were associated with splenectomy and 
chelation therapy 
• Poor diets likely further exacerbate antioxidant deficiency 
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